Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Public ClinicalTrials.gov record NCT03875183. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Study identification
- NCT ID
- NCT03875183
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2020
- Primary completion
- Nov 30, 2022
- Completion
- Dec 31, 2022
- Last update posted
- Mar 30, 2022
2020 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA School of Medicine | Torrance | California | 90502 | Active, not recruiting |
| Innovative Research of West Florida, Inc. | Clearwater | Florida | 33756 | Completed |
| Universal Axon Clinical Research | Doral | Florida | 33166 | Withdrawn |
| Grady Clinical Research Center | Atlanta | Georgia | 30303 | Completed |
| Via Christi Research, a division of Via Christi Hospitals Wichita, Inc. | Wichita | Kansas | 67214 | Withdrawn |
| Clinical Trials of America LA, LLC | Monroe | Louisiana | 71203 | Withdrawn |
| St Louis Heart and Vascular | St Louis | Missouri | 63136 | Completed |
| Clinical Research of Gastonia | Gastonia | North Carolina | 28054 | Completed |
| Medication Management, LLC | Greensboro | North Carolina | 27401 | Withdrawn |
| Stern Cardiovascular | Germantown | Tennessee | 38138 | Withdrawn |
| East Texas Cardiology | Houston | Texas | 77002 | Completed |
| Angiocardiac Care of Texas | Houston | Texas | 77025 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03875183, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2022 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03875183 live on ClinicalTrials.gov.